Ideaya Biosciences Inc. (IDYA)
Summary
IDEAYA Biosciences, Inc. (IDYA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
IDEAYA Biosciences, Inc. (IDYA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Ideaya Biosciences: Darovasertib De-Risks A Self-Reinforcing Oncology Platform
IDEAYA Biosciences is transitioning into a commercial oncology platform, leveraging darovasertib's registrational success and a robust internal pipeline. Darovasertib's phase 2 trial showed a median PFS of 6.9 vs. 3.1 months, supporting NDA submission and U.S. commercialization prospects. With $1.24 billion in cash, IDYA can fund operations into 2030, enabling the advancement of multiple proprietary combination franchises.
IDEAYA Biosciences Spotlights Darovasertib Win, FDA Review Path at Oncology Summit
IDEAYA Biosciences NASDAQ: IDYA executives highlighted recent clinical progress across the company's oncology pipeline during a fireside chat at TD Cowen's seventh annual Oncology Innovation Summit, with the discussion focused primarily on darovasertib combinations in uveal melanoma and several earlier-stage antibody-drug conjugate and synthetic lethality programs.
Ideaya Biosciences Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 176 | $4,010.91 | $6,591.2 | $2,580.29 | 64.33% |
| NA Nizar Araji National Bank Of Canada /FI/ | 113 | $3,490.15 | $4,181.57 | $691.42 | 19.81% |
| BG Bart Gancher Intech Investment Management LLC | 21,858 | $418,752.26 | $808,855.31 | $390,103.05 | 93.16% |
 John H. Burbank III Passport Capital LLC | 5.01M | $126.44M | $199.77M | $73.33M | 58% |
| YA Yinka Akinsola Blue Trust Inc. | 32 | $672.64 | $1,202.47 | $529.83 | 78.77% |
Ideaya Biosciences Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Robert Driscoll Wedbush | 665.27 | $23,616.92 | $24,914.19 | $1,297.27 | 5.49% |
| GR Gregory Renza Truist Securities | 91.21 | $3,694.91 | $3,613.54 | -$81.37 | -2.2% |
Ideaya Biosciences Inc. (IDYA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Ideaya Biosciences Inc. ever had a stock split?
Ideaya Biosciences Inc. Profile
| Biotechnology Industry | Healthcare Sector | Yujiro S. Hata CEO | NASDAQ (NGS) Exchange | 45166A102 CUSIP |
| US Country | 145 Employees | - Last Dividend | - Last Split | 23 May 2019 IPO Date |
Overview
IDEAYA Biosciences, Inc. is a precision medicine oncology company with a focused approach on synthetic lethality to discover and develop targeted therapeutics. It aims to serve patient populations selected through molecular diagnostics within the United States. The company's innovative approach leverages advanced technologies and strategic alliances with major pharmaceuticals and research organizations. Founded in 2015, IDEAYA Biosciences is strategically headquartered in South San Francisco, California, positioning it at the heart of biotechnological innovation. Its collaborations span across industry leaders such as GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., along with esteemed academic institutions such as Cancer Research UK and the University of Manchester. These partnerships underscore its commitment to advancing cancer treatment through cutting-edge research and drug development.
Products and Services
- IDE196: A protein kinase C inhibitor currently under Phase 2/3 clinical trials. It targets genetically defined cancers characterized by GNAQ or GNA11 gene mutations, which are prevalent in certain melanomas and uveal melanomas.
- IDE397: A methionine adenosyltransferase 2a inhibitor in Phase 1/2 clinical trials. It focuses on patients with solid tumors that have deletions in the methylthioadenosine phosphorylase gene, affecting cancers like non-small cell lung, bladder, gastric, and esophageal cancers.
- IDE161: A poly ADP-ribose glycohydrolase (PARG) inhibitor in Phase 1 clinical trials. It is intended for tumors characterized by homologous recombination deficiency (HRD) and other genetic or molecular signatures.
- GSK101: In collaboration with GlaxoSmithKline, this Pol Theta helicase inhibitor is in Phase 1 clinical trial for tumors with BRCA mutations, other homologous recombination, and HRD mutations.
- Werner Helicase inhibitors: Focused on tumors with high microsatellite instability, these inhibitors are part of the company’s preclinical research. They target a rare but critical weakness in certain cancer types.
By inhibiting the protein kinase C pathway, IDE196 aims to impede the growth of cancer cells with specific genetic mutations, providing a targeted approach to treating these aggressive cancers.
IDE397's mechanism seeks to exploit the tumor's methionine dependency, potentially leading to a novel treatment avenue for these challenging solid tumor cancers.
This therapeutic approach aims to exploit the vulnerability of HRD tumors to DNA damage, offering a promising direction for patients with limited treatment options.
GSK101 explores the potential of inhibiting the DNA repair pathway in cancer cells, specifically targeting those with compromised DNA repair mechanisms for targeted cancer therapy.
By targeting Werner Helicase, these inhibitors aim at exploiting the unique replication stress inherent in these tumors, providing a new angle for therapeutic intervention.
In addition to these products, IDEAYA Biosciences enriches its drug discovery platform with proprietary technologies such as the DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery, the INQUIRE chemical library, and the HARMONY machine-learning engines. These innovative tools underscore the company’s leading edge in identifying and advancing novel oncology therapeutics.
